## **Baylor College of Medicine**



## DNA elements IDed that affect MECP2 expression

Graciela Gutierrez 713-798-4710

Houston, TX - Mar 18, 2021

Share this article in 😯

Researchers at Baylor College of Medicine and the Jan and Dan Duncan <u>Neurological Research Institute</u> at <u>Texas Children's Hospital</u> (NRI) have identified and characterized two regions of DNA required for the proper expression of Mecp2/MECP2 in mice and humans.

These findings, published in <u>Genes & Development</u>, are helping to shed light on the function of these DNA regions and how they could be potential targets for diagnostic and therapeutic interventions for intellectual disabilities such as Rett Syndrome and MECP2 Duplication Syndrome.

Both of these intellectual disabilities are examples of the importance of precise MeCP2 protein levels for proper brain function. A decrease in this protein leads to Rett Syndrome, while an increase in this protein causes MECP2 Duplication Syndrome. Both are severe neurological disorders characterized by learning disabilities, features of autism and motor difficulties.

<u>Dr. Huda Zoghbi</u>, professor at Baylor, director of the NRI, and a Howard Hughes Medical Institute investigator, underscored the importance of understanding how the levels of RNA encoding this protein are regulated. Researchers in her lab identified two DNA regions that, when mutated, lead to either a decrease or an increase in MECP2 RNA and protein levels, resulting in partial behavioral deficits seen in Rett Syndrome and MECP2 Duplication Syndrome, respectively.

Yingyao Shao, first author on the study and graduate student in the Zoghbi lab, explains that when one of the two DNA regions were altered, results showed a moderate reduction in MeCP2 levels mimicking behavioral and molecular changes observed in Rett mice models. Alteration of the other DNA region caused a slight increase in MeCP2 protein levels similar to mice models with double expression of MeCP2. Others who contributed to this study include Dr. Sameer S. Bajikar, Harini P. Tirumala, Manuel Cantu Gutierrez and Dr. Joshua D. Wythe, with the Jan and Dan Duncan Neurological Research Institute and/or Baylor College of Medicine.

Funding provided by the National Institutes of Health (5R01NS057819 to HYZ, 1F32HD100048-01 to SSB), American Heart Association (19PRE34410104 to MCG), Institutional startup funds (JDW), Department of Defense (W81XWH-18-1-0350 to JDW), CIHR (PJT 155922 to JDW), the Howard Hughes Medical Institute (HYZ), the Baylor College of Medicine Intellectual and Developmental Disabilities Research Center (NIH 5P50HD103555), the Henry Engel Fund and the Ziff Family Fund.

©1998-2020 Baylor College of Medicine® One Baylor Plaza, Houston, Texas 77030 (713)798-4951

Have an edit or suggestion for this page?